Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Maryland Franklin, Suso Platero, Kamal S. Saini, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003231-e003231
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Novel targets for immune-checkpoint inhibition in cancer
Maxime Borgeaud, José Luís Sandoval, Michel Obéid, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102614-102614
Open Access | Times Cited: 53
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review
Daniele Presti, Filippo Gustavo Dall’Olio, Benjamin Besse, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 177, pp. 103773-103773
Closed Access | Times Cited: 50
Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation
Muhammad Javed Iqbal, Zeeshan Javed, Jesús Herrera‐Bravo, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 47
Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC
Yuqi Yang, Tianjiao Zhao, Qiaohui Chen, et al.
Advanced Science (2022) Vol. 9, Iss. 28
Open Access | Times Cited: 39
Structural Requirements of Isoform-Specific Inhibitors of Akt: Implications in the Development of Effective Cancer Treatment Strategies
Tenzin Adon, Syamal D. Bhattacharya, SubbaRao V. Madhunapantula, et al.
European Journal of Medicinal Chemistry (2025), pp. 117334-117334
Closed Access | Times Cited: 1
A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model
Monica Marzagalli, Giorgia Pelizzoni, Arianna Fedi, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 32
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
Paul Hofman, Sabina Berezowska, Daniel Kazdal, et al.
Virchows Archiv (2023) Vol. 484, Iss. 2, pp. 233-246
Open Access | Times Cited: 20
Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms
Filippo Torrisi, Simona D’Aprile, Simona Denaro, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 220-220
Open Access | Times Cited: 16
Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy
Jeremy McGale, Harrison J. Howell, Arnaud Beddok, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 210-210
Open Access | Times Cited: 6
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
ImpACT Project: Improving Access to Clinical Trials in Victoria, an Artificial Intelligence–Based Approach
Maria L. Bechelli, Kris Ivanova, Sze An Peter Tan, et al.
JCO Clinical Cancer Informatics (2025), Iss. 9
Closed Access
Exploring the potential of bi-specific antibodies in cancer immunotherapy
Kirolos Eskandar
Surgery and Oncology (2025) Vol. 15, Iss. 1, pp. 11-17
Closed Access
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies
Hanrui Wang, Xiaoyu Song, Hui Shen, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Annachiara Dozzo, Aoife Galvin, Jae‐Won Shin, et al.
Drug Delivery and Translational Research (2022) Vol. 13, Iss. 8, pp. 2110-2141
Open Access | Times Cited: 22
In vitro and in vivo experimental models for cancer immunotherapy study
Chunye Zhang, Yuxiang Sui, Shuai Liu, et al.
Current Research in Biotechnology (2024) Vol. 7, pp. 100210-100210
Open Access | Times Cited: 4
Immunotherapy in Recurrent Ovarian Cancer
Keyao Chen, Jingjing Wang, Meng Yang, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 168-168
Open Access
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges
Celine Man Ying Li, Runhao Li, Paul A. Drew, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102665-102665
Closed Access | Times Cited: 8
Biomarkers and experimental models for cancer immunology investigation
Hengyi Xu, Ziqi Jia, Fengshuo Liu, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 8
Exploration of Dan-Shen-Yin against pancreatic cancer based on network pharmacology combined with molecular docking and experimental validation
Ao Gu, Jiatong Li, Jian-An Wu, et al.
Current Research in Biotechnology (2024) Vol. 7, pp. 100228-100228
Open Access | Times Cited: 2
A Comprehensive Review on PARP Inhibitors in Targeted Therapy for Cancers
Mounika Guduri, Samyuktha Kolluru, Haritha Pasupulati, et al.
Deleted Journal (2024) Vol. 19, Iss. 2, pp. 44-59
Open Access | Times Cited: 2
The role of ncRNAs and exosomes in the development and progression of endometrial cancer
Julia Niebora, Sławomir Woźniak, Dominika Domagała, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model
Xiaojie Gan, Dongyang Ding, Mengchao Wang, et al.
Cancer Letters (2022) Vol. 550, pp. 215930-215930
Closed Access | Times Cited: 10
PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo
Yan Wang, Xavier Rousset, Chloé Prunier, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3095-3095
Open Access | Times Cited: 9
Tumour induction in BALB/c mice for imaging studies: An improved protocol
Abolfazl Amini, Gholamreza Mesbah, Fatemeh T. Shamsabadi, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 13, pp. 1880-1886
Open Access | Times Cited: 4
Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
Arun K. Mankan, N. Mankan, Begoña de las Heras, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 885-890
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top